William Meury - Aug 2, 2023 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
Director
Signature
/s/ Michael A. Metzger, as Attorney-in-Fact
Stock symbol
SNDX
Transactions as of
Aug 2, 2023
Transactions value $
-$1,032,560
Form type
4
Date filed
8/3/2023, 09:12 AM
Previous filing
Feb 3, 2023
Next filing
Dec 29, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Options Exercise $249K +35K +72.92% $7.11 83K Aug 2, 2023 Direct
transaction SNDX Common Stock Sale -$716K -35K -42.17% $20.46 48K Aug 2, 2023 Direct F1
transaction SNDX Common Stock Options Exercise $189K +24K +50% $7.88 72K Aug 2, 2023 Direct
transaction SNDX Common Stock Sale -$491K -24K -33.33% $20.46 48K Aug 2, 2023 Direct F2
transaction SNDX Common Stock Options Exercise $227K +24K +50% $9.47 72K Aug 2, 2023 Direct
transaction SNDX Common Stock Sale -$491K -24K -33.33% $20.45 48K Aug 2, 2023 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -24K -100% $0.00* 0 Aug 2, 2023 Common Stock 24K $9.47 Direct F4
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -24K -100% $0.00* 0 Aug 2, 2023 Common Stock 24K $7.88 Direct F4
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -35K -100% $0.00* 0 Aug 2, 2023 Common Stock 35K $7.11 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale prices ranged from $20.29 to $21.00.
F2 The sale prices ranged from $20.30 to $20.97.
F3 The sale prices ranged from $20.2950 to $20.89.
F4 This option is fully vested.